IP Library › Granted Patent US 8,715,953
Granted Patent B2
US 8,715,953 · App. 14/070,257 · Granted May 6, 2014

Analysis of sulfated polysaccharides

Inventors: Ganesh Kaundinya (Bedford, MA); Zachary Shriver (Cambridge, MA); Mallikarjun Sundaram (Flemington, NJ); Yi-wei Qi (Manlius, NY); Ram Sasisekharan (Cambridge, MA)
Assignee: Momenta Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,953
App. No.
14/070,257
Granted
May 6, 2014
Kind
B2
Abstract

The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.

Claims (10)

1. A method of producing an enoxaparin pharmaceutical composition, the method comprising:

producing a batch of low molecular weight heparin (LMWH) by β-eliminative cleavage of a heparin preparation;

exhaustively digesting a sample of the batch of LMWH with two or more heparin degrading enzymes;

using a separation method to determine, in the sample that has been digested with two or more heparin degrading enzymes, the presence of a structural signature associated with the non naturally occurring sugar associated with peak 9 of FIG. 1 that results from β-eliminative cleavage;

selecting the batch of LMWH as a batch of enoxaparin if the non naturally occurring sugar associated with peak 9 is present in the sample compared to a pre-selected value for enoxaparin; and

formulating the selected batch of enoxaparin for medical use, thereby producing an enoxaparin pharmaceutical composition.

2. The method of claim 1 , wherein formulating comprises combining the batch of enoxaparin with a pharmaceutically acceptable carrier.

3. The method of claim 1 , wherein the preselected value is an enoxaparin reference standard.

4. The method of claim 1 , wherein the structural signature is determined using High Performance Liquid Chromatography (HPLC).

5. The method of claim 1 , wherein the structural signature is determined using Capillary Electrophoresis (CE).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2014
From: KAUNDINYA, GANESH; SASISEKHARAN, RAM; SUNDARAM, MALLIKARJUN; SHRIVER, ZACHARY; QI, YI-WEI
To: MOMENTA PHARMACEUTICALS, INC.
Reel/Frame 031995/0362 →
Continuity (8)
Continuation 13602979 · Sep 4, 2012
Continuation 13086054 · Apr 13, 2011
Continuation 12203629 · Sep 3, 2008
Continuation 10386402 · Mar 11, 2003
Provisional Application 60363240 · Mar 11, 2002
Provisional Application 60383903 · May 28, 2002
Provisional Application 60393973 · Jul 5, 2002
Related Publication 20140057358A1 · Feb 27, 2014